Inclusion Criteria:

          -  Subjects with a histologically confirmed diagnosis of ACPP or CPC that is newly
             diagnosed, residual or recurrent.

          -  Subjects must have a Karnofsky or Lansky Performance Score ≥ 60 % assessed within two
             weeks prior to enrollment. Karnofsky is used for patients ≥ 16 years and Lansky for
             those < 16.

          -  Subjects must have normal organ and marrow function documented within 14 days of
             enrollment and within 7 days of the start of treatment as noted below:

               1. Absolute neutrophil count ≥ 1,000/μL

               2. Platelets ≥ 100,000/μL (transfusion independent, defined as not receiving
                  platelet transfusions within a 7-day period prior to enrollment)

               3. Hemoglobin ≥ 8 g/dL (may receive PRBC transfusions)

               4. Total bilirubin < 1.5 times upper limit of normal for age

               5. AST (SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal for age

               6. Creatinine clearance or radioisotope GFR ≥ 70 ml/min/1.73m2 or a serum creatinine
                  WNL for age as determined using the Schwartz formula.36

               7. Sodium, Potassium, Calcium and Magnesium < 1.5x institutional ULN

               8. Albumin ≥ 3 g/dL

          -  Subjects must have adequate cardiac function defined as:

               -  LVEF ≥ 50%

               -  QTc interval ≤ 450 msecs

          -  Subjects greater than 3 years of age must have a blood pressure that is ≤ 95th
             percentile for age, height and gender at the time of enrollment.

          -  Subjects who are receiving dexamethasone must be on a stable or decreasing dose for at
             least 1 week prior to enrollment.

          -  Subjects with neurological deficits should have deficits that are stable for a minimum
             of 1 week prior to enrollment.

          -  If the subject has any of the following therapies, must be at least:

               -  4 weeks post-focal RT (radiation therapy), 3 months post-CSI (craniospinal
                  irradiation)

               -  4 weeks post-myelosuppressive chemotherapy (if post-nitrosoureas, must have 6
                  weeks therapy)

               -  4 weeks post-monoclonal antibodies

               -  1 week post-targeted therapy

          -  If subject has received any previous treatment, all treatment related toxicities
             should have recovered to < grade 2

          -  Subject or parent must sign a written informed consent document according to
             institutional guidelines.

        Exclusion Criteria:

          -  Females who are pregnant or lactating.

          -  Subjects with any clinically significant unrelated systemic illness (serious
             infections or significant cardiac, pulmonary, hepatic or other organ dysfunction)
             likely to interfere with the study procedures or results.

          -  Subjects who are receiving any other anticancer or investigational agents.

          -  Subjects with uncontrolled seizures.

          -  Subjects receiving enzyme inducing anticonvulsants.

          -  Subjects with other factors that increase the risk of QT prolongation or arrhythmic
             events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome)
             including heart failure that meets New York Heart Association (NYHA) class II or
             above.

          -  Subjects who have had an allogenic bone marrow transplant < 6 months prior to
             enrollment or an autologous bone marrow/stem cell transplant < 3 months prior to
             enrollment.

          -  Subjects with multifocal disease or disease that has been disseminated will not be
             eligible for this study. They will undergo systemic chemotherapy and their disease
             will be further evaluated prior to be eligible for 2nd look surgery.

          -  This study will only enroll subjects with ACPP or CPC and will not enroll subjects
             with choroid plexus papilloma (CPP). ACPP or CPC subjects diagnosed with hydrocephalus
             or are presented with clinical symptoms of hydrocephalus will not be eligible for this
             study. These subjects will have to be treated for their hydrocephalus and be
             re-evaluated according to our eligibility criteria in order to be enrolled.